NCT04176016View on ClinicalTrials.gov

Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

January 11, 2024

Study Completion Date

January 11, 2024

Conditions
Relapsed or Refractory Synovial Sarcoma
Interventions
DRUG

OTSA101-DTPA-111In

single IV injection, 185MBq/body

DRUG

OTSA101-DTPA-90Y

IV injection (max. 3 injections per patient), 1110MBq/body

Trial Locations (3)

Unknown

Osaka International Cancer Institute, Osaka

Cancer Institute Hospital of JFCR, Tokyo

National Cancer Center Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

OncoTherapy Science, Inc.

INDUSTRY

NCT04176016 - Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma | Biotech Hunter | Biotech Hunter